Immunovant, Inc. (IMVT) 10-Year Financial Performance & Capital Metrics

IMVT • • Industrial / General

HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesDermatology & Autoimmune

AboutImmunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.Show more

Revenue $0
EBITDA -$438M -62.2%
Net Income -$414M -59.6%
EPS (Diluted) -2.73 -45.2%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -62.46% -18.0%
ROIC -
Debt/Equity 0.00 -37.7%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 87 (top 13%)

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-43.86%

EPS CAGR

10Y-

5Y-

3Y-

TTM-27.93%

ROCE

10Y Avg-54.33%

5Y Avg-50.32%

3Y Avg-57.06%

Latest-66.11%

Peer Comparison

Dermatology & Autoimmune

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
AUPHAurinia Pharmaceuticals Inc.	1.96B	14.87	378.37	33.97%	29.28%	21.28%	2.25%	0.21
ARGXargenx SE	50.33B	813.24	63.63	78.6%	23.34%	15.14%		0.01
INVAInnoviva, Inc.	1.48B	19.76	54.89	15.54%	32.78%	12.61%	12.75%	0.65
GLPGGalapagos N.V.	2.24B	34.03	30.38	14.99%	-151.94%	-15.16%		0.00
PTGXProtagonist Therapeutics, Inc.	5.3B	84.75	20.04	6.24%	21.94%	7.11%	3.45%	0.02
ALMSAlumis Inc. Common Stock	2.84B	24.17	-2.33		-11.08%	-63.71%		0.12
PHATPhathom Pharmaceuticals, Inc.	1.17B	14.98	-2.83	80.01%	-186.53%
ORKAOruka Therapeutics, Inc.	1.57B	32.50	-6.51			-22.44%		0.00

Profit & Loss

	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Sales/Revenue+	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-
Cost of Goods Sold+	0	0	21K	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-
Gross Profit+	0	0	-21K	0	0	0	0	0
Gross Margin %	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	-	-	1%	-	-	-	-
Operating Expenses+	136.74M	448	59.66M	108.12M	156.03M	208.28M	270.21M	438.15M
OpEx % of Revenue	-	-	-	-	-	-	-	-
Selling, General & Admin	1.48M	448	11.73M	39.51M	54.23M	48.02M	57.28M	77.23M
SG&A % of Revenue	-	-	-	-	-	-	-	-
Research & Development	135.26M	25.73M	47.93M	68.6M	101.81M	160.26M	212.93M	360.92M
R&D % of Revenue	-	-	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0	0	0	0
Operating Income+	-136.74M	-450	-59.68M	-108.12M	-156.03M	-208.28M	-270.21M	-438.15M
Operating Margin %	-	-	-	-	-	-	-	-
Operating Income Growth %	-	1%	-132616.78%	-0.81%	-0.44%	-0.33%	-0.3%	-0.62%
EBITDA+	0	9.55K	-59.66M	-108.05M	-155.91M	-208.08M	-269.98M	-437.77M
EBITDA Margin %	-	-	-	-	-	-	-	-
EBITDA Growth %	-	-	-6247.81%	-0.81%	-0.44%	-0.33%	-0.3%	-0.62%
D&A (Non-Cash Add-back)	136.74M	10K	21K	65K	126K	193K	231K	377K
EBIT	-136.74M	-448	-65.67M	-108.12M	-156.03M	-208.28M	-270.21M	-438.15M
Net Interest Income+	0	0	-624.38K	0	0	-4.9M	24.95M	24.73M
Interest Income	0	0	625	0	-	7.58M	24.95M	24.73M
Interest Expense	0	0	625K	0	-	12.48M	0	0
Other Income/Expense	116	0	-6.61M	328K	-781K	-2.67M	11.44M	25.2M
Pretax Income+	-136.74M	-448	-66.29M	-107.79M	-156.81M	-210.95M	-258.77M	-412.95M
Pretax Margin %	-	-	-	-	-	-	-	-
Income Tax+	0	0	97K	-358K	-84K	9K	567K	891K
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-136.74M	-448	-66.39M	-107.43M	-156.73M	-210.96M	-259.34M	-413.84M
Net Margin %	-	-	-	-	-	-	-	-
Net Income Growth %	-	1%	-148186.5%	-0.62%	-0.46%	-0.35%	-0.23%	-0.6%
Net Income (Continuing)	-136.74M	-448	-66.39M	-107.43M	-156.73M	-210.96M	-259.34M	-413.84M
Discontinued Operations	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0
EPS (Diluted)+	-13.67	0.00	-1.54	-1.22	-1.43	-1.71	-1.88	-2.73
EPS Growth %	-	1%	-	0.21%	-0.17%	-0.2%	-0.1%	-0.45%
EPS (Basic)	-13.68	0.00	-1.54	-1.22	-1.43	-1.71	-1.88	-2.73
Diluted Shares Outstanding	10M	14.38M	43.2M	87.76M	109.68M	123.08M	138.1M	151.57M
Basic Shares Outstanding	10M	14.38M	43.2M	87.76M	109.68M	123.08M	138.1M	151.57M
Dividend Payout Ratio	-	-	-	-	-	-	-	-

Balance Sheet

	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Total Current Assets+	113.17K	325K	109.08M	409.01M	512.93M	404.33M	665.77M	767.66M
Cash & Short-Term Investments	0	325K	100.57M	400.15M	493.82M	376.53M	635.37M	713.97M
Cash Only	0	325K	100.57M	400.15M	493.82M	376.53M	635.37M	713.97M
Short-Term Investments	0	0	0	0	0	0	0	0
Accounts Receivable	0	0	3.04M	1.14M	12.86M	885K	5.5M	2.51M
Days Sales Outstanding	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-
Other Current Assets	0	0	0	0	0	0	24.9M	51.18M
Total Non-Current Assets+	0	80K	311K	3.48M	2.63M	1.5M	942K	8.56M
Property, Plant & Equipment	0	0	65K	3.48M	2.63M	1.5M	595K	942K
Fixed Asset Turnover	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0
Other Non-Current Assets	0	79.95K	246K	0	0	0	0	7.62M
Total Assets+	113.17K	405K	109.39M	412.49M	515.56M	405.84M	666.71M	776.22M
Asset Turnover	-	-	-	-	-	-	-	-
Asset Growth %	-	2.58%	269.09%	2.77%	0.25%	-0.21%	0.64%	0.16%
Total Current Liabilities+	1.61M	380.45K	15.32M	18.77M	44.52M	43.3M	48.61M	68.78M
Accounts Payable	1.14M	0	1.19M	2.43M	18.63M	1.35M	7.16M	17.66M
Days Payables Outstanding	-	-	20.68K	-	-	-	-	-
Short-Term Debt	0	300K	3.19M	0	0	0	138K	0
Deferred Revenue (Current)	0	-206	0	0	0	0	0	0
Other Current Liabilities	0	-206	10.94M	3.14M	171K	350K	26.57M	15.62M
Current Ratio	0.07x	0.85x	7.12x	21.79x	11.52x	9.34x	13.70x	11.16x
Quick Ratio	0.07x	0.85x	7.12x	21.79x	11.52x	9.34x	13.70x	11.16x
Cash Conversion Cycle	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	0	300K	0	2.24M	1.22M	47K	347K	0
Long-Term Debt	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	2.24M	1.22M	47K	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	347K	0
Other Non-Current Liabilities	0	0	0	0	0	0	0	0
Total Liabilities	1.61M	380.45K	15.32M	21.01M	45.74M	43.34M	48.95M	68.78M
Total Debt+	0	300K	3.19M	3.42M	2.36M	1.22M	138K	98K
Net Debt	0	-25K	-97.38M	-396.73M	-491.45M	-375.31M	-635.23M	-713.87M
Debt / Equity	-	12.22x	0.03x	0.01x	0.01x	0.00x	0.00x	0.00x
Debt / EBITDA	-	31.41x	-	-	-	-	-	-
Net Debt / EBITDA	-	-2.62x	-	-	-	-	-	-
Interest Coverage	-	-	-95.48x	-	-	-16.69x	-	-
Total Equity+	-1.5M	24.55K	94.07M	391.48M	469.82M	362.49M	617.76M	707.45M
Equity Growth %	-	1.02%	3830.42%	3.16%	0.2%	-0.23%	0.7%	0.15%
Book Value per Share	-0.15	0.00	2.18	4.46	4.28	2.95	4.47	4.67
Total Shareholders' Equity	-1.5M	24.55K	94.07M	391.48M	469.82M	362.49M	617.76M	707.45M
Common Stock	0	288	5K	10K	12K	13K	14K	16K
Retained Earnings	0	-448	-91.23M	-198.66M	-355.39M	-566.35M	-825.68M	-1.24B
Treasury Stock	0	0	0	0	0	0	0	0
Accumulated OCI	-1.5M	343K	-16K	-298K	404K	852K	1.91M	1.46M
Minority Interest	0	0	0	0	0	0	0	0

Cash Flow

	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operations+	-128.3M	-28.55M	-53.36M	-83.33M	-106.11M	-188.19M	-214.23M	-375.87M
Operating CF Margin %	-	-	-	-	-	-	-	-
Operating CF Growth %	-	0.78%	-0.87%	-0.56%	-0.27%	-0.77%	-0.14%	-0.75%
Net Income	-136.74M	-28.6M	-66.39M	-107.43M	-156.73M	-210.96M	-259.34M	-413.84M
Depreciation & Amortization	0	10K	21K	998K	126K	193K	231K	377K
Stock-Based Compensation	1.81M	1.31M	6.96M	0	34.24M	32.3M	41.12M	49.49M
Deferred Taxes	0	0	0	0	0	0	0	0
Other Non-Cash Items	5.19M	-792K	1.24M	18.54M	1.11M	1.13M	1.13M	133K
Working Capital Changes	1.44M	-474K	4.81M	4.57M	15.14M	-10.85M	2.63M	-12.03M
Change in Receivables	0	0	-83K	2.5M	-11.72M	12.22M	-4.56M	2.97M
Change in Inventory	0	0	0	0	0	0	0	0
Change in Payables	0	0	967K	1.25M	16.25M	-17.12M	5.78M	10.68M
Cash from Investing+	0	-52K	-31K	-210K	-254K	-197K	-360K	-759K
Capital Expenditures	0	-52K	-31K	-210K	-254K	-197K	-360K	-759K
CapEx % of Revenue	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0	0	0
Cash from Financing+	128.3M	35.58M	146.97M	383.11M	200.13M	70.89M	472.43M	454.49M
Debt Issued (Net)	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-
Other Financing	128.3M	35.58M	109.07M	0	200.13M	385K	-318K	4.49M
Net Change in Cash	-	-	-	-	-	-	-	-
Free Cash Flow+	-128.3M	-28.6M	-53.39M	-83.54M	-106.37M	-188.39M	-214.59M	-376.63M
FCF Margin %	-	-	-	-	-	-	-	-
FCF Growth %	-	0.78%	-0.87%	-0.56%	-0.27%	-0.77%	-0.14%	-0.76%
FCF per Share	-12.83	-1.99	-1.24	-0.95	-0.97	-1.53	-1.55	-2.48
FCF Conversion (FCF/Net Income)	0.94x	63720.98x	0.80x	0.78x	0.68x	0.89x	0.83x	0.91x
Interest Paid	0	0	0	0	0	0	0	0
Taxes Paid	0	0	61K	0	0	0	509K	1.2M

Key Ratios

Metric	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	-	-1.82%	-141.11%	-44.25%	-36.39%	-50.69%	-52.91%	-62.46%
Debt / Equity	-	12.22x	0.03x	0.01x	0.01x	0.00x	0.00x	0.00x
Interest Coverage	-	-	-95.48x	-	-	-16.69x	-	-
FCF Conversion	0.94x	63720.98x	0.80x	0.78x	0.68x	0.89x	0.83x	0.91x

Frequently Asked Questions

Growth & Financials

Immunovant, Inc. (IMVT) grew revenue by 0.0% over the past year. Growth has been modest.

Immunovant, Inc. (IMVT) reported a net loss of $464.7M for fiscal year 2025.

Dividend & Returns

Immunovant, Inc. (IMVT) has a return on equity (ROE) of -62.5%. Negative ROE indicates the company is unprofitable.

Immunovant, Inc. (IMVT) had negative free cash flow of $431.3M in fiscal year 2025, likely due to heavy capital investments.

← Back to Screener

US Stock Screener

...

Immunovant, Inc. (IMVT) 10-Year Financial Performance & Capital Metrics

IMVT • • Industrial / General

HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesDermatology & Autoimmune

Revenue $0
EBITDA -$438M -62.2%
Net Income -$414M -59.6%
EPS (Diluted) -2.73 -45.2%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -62.46% -18.0%
ROIC -
Debt/Equity 0.00 -37.7%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 87 (top 13%)

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-43.86%

EPS CAGR

10Y-

5Y-

3Y-

TTM-27.93%

ROCE

10Y Avg-54.33%

5Y Avg-50.32%

3Y Avg-57.06%

Latest-66.11%

Peer Comparison

Dermatology & Autoimmune

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
AUPHAurinia Pharmaceuticals Inc.	1.96B	14.87	378.37	33.97%	29.28%	21.28%	2.25%	0.21
ARGXargenx SE	50.33B	813.24	63.63	78.6%	23.34%	15.14%		0.01
INVAInnoviva, Inc.	1.48B	19.76	54.89	15.54%	32.78%	12.61%	12.75%	0.65
GLPGGalapagos N.V.	2.24B	34.03	30.38	14.99%	-151.94%	-15.16%		0.00
PTGXProtagonist Therapeutics, Inc.	5.3B	84.75	20.04	6.24%	21.94%	7.11%	3.45%	0.02
ALMSAlumis Inc. Common Stock	2.84B	24.17	-2.33		-11.08%	-63.71%		0.12
PHATPhathom Pharmaceuticals, Inc.	1.17B	14.98	-2.83	80.01%	-186.53%
ORKAOruka Therapeutics, Inc.	1.57B	32.50	-6.51			-22.44%		0.00

Profit & Loss

	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Sales/Revenue+	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-
Cost of Goods Sold+	0	0	21K	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-
Gross Profit+	0	0	-21K	0	0	0	0	0
Gross Margin %	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	-	-	1%	-	-	-	-
Operating Expenses+	136.74M	448	59.66M	108.12M	156.03M	208.28M	270.21M	438.15M
OpEx % of Revenue	-	-	-	-	-	-	-	-
Selling, General & Admin	1.48M	448	11.73M	39.51M	54.23M	48.02M	57.28M	77.23M
SG&A % of Revenue	-	-	-	-	-	-	-	-
Research & Development	135.26M	25.73M	47.93M	68.6M	101.81M	160.26M	212.93M	360.92M
R&D % of Revenue	-	-	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0	0	0	0
Operating Income+	-136.74M	-450	-59.68M	-108.12M	-156.03M	-208.28M	-270.21M	-438.15M
Operating Margin %	-	-	-	-	-	-	-	-
Operating Income Growth %	-	1%	-132616.78%	-0.81%	-0.44%	-0.33%	-0.3%	-0.62%
EBITDA+	0	9.55K	-59.66M	-108.05M	-155.91M	-208.08M	-269.98M	-437.77M
EBITDA Margin %	-	-	-	-	-	-	-	-
EBITDA Growth %	-	-	-6247.81%	-0.81%	-0.44%	-0.33%	-0.3%	-0.62%
D&A (Non-Cash Add-back)	136.74M	10K	21K	65K	126K	193K	231K	377K
EBIT	-136.74M	-448	-65.67M	-108.12M	-156.03M	-208.28M	-270.21M	-438.15M
Net Interest Income+	0	0	-624.38K	0	0	-4.9M	24.95M	24.73M
Interest Income	0	0	625	0	-	7.58M	24.95M	24.73M
Interest Expense	0	0	625K	0	-	12.48M	0	0
Other Income/Expense	116	0	-6.61M	328K	-781K	-2.67M	11.44M	25.2M
Pretax Income+	-136.74M	-448	-66.29M	-107.79M	-156.81M	-210.95M	-258.77M	-412.95M
Pretax Margin %	-	-	-	-	-	-	-	-
Income Tax+	0	0	97K	-358K	-84K	9K	567K	891K
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-136.74M	-448	-66.39M	-107.43M	-156.73M	-210.96M	-259.34M	-413.84M
Net Margin %	-	-	-	-	-	-	-	-
Net Income Growth %	-	1%	-148186.5%	-0.62%	-0.46%	-0.35%	-0.23%	-0.6%
Net Income (Continuing)	-136.74M	-448	-66.39M	-107.43M	-156.73M	-210.96M	-259.34M	-413.84M
Discontinued Operations	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0
EPS (Diluted)+	-13.67	0.00	-1.54	-1.22	-1.43	-1.71	-1.88	-2.73
EPS Growth %	-	1%	-	0.21%	-0.17%	-0.2%	-0.1%	-0.45%
EPS (Basic)	-13.68	0.00	-1.54	-1.22	-1.43	-1.71	-1.88	-2.73
Diluted Shares Outstanding	10M	14.38M	43.2M	87.76M	109.68M	123.08M	138.1M	151.57M
Basic Shares Outstanding	10M	14.38M	43.2M	87.76M	109.68M	123.08M	138.1M	151.57M
Dividend Payout Ratio	-	-	-	-	-	-	-	-

Balance Sheet

	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Total Current Assets+	113.17K	325K	109.08M	409.01M	512.93M	404.33M	665.77M	767.66M
Cash & Short-Term Investments	0	325K	100.57M	400.15M	493.82M	376.53M	635.37M	713.97M
Cash Only	0	325K	100.57M	400.15M	493.82M	376.53M	635.37M	713.97M
Short-Term Investments	0	0	0	0	0	0	0	0
Accounts Receivable	0	0	3.04M	1.14M	12.86M	885K	5.5M	2.51M
Days Sales Outstanding	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-
Other Current Assets	0	0	0	0	0	0	24.9M	51.18M
Total Non-Current Assets+	0	80K	311K	3.48M	2.63M	1.5M	942K	8.56M
Property, Plant & Equipment	0	0	65K	3.48M	2.63M	1.5M	595K	942K
Fixed Asset Turnover	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0
Other Non-Current Assets	0	79.95K	246K	0	0	0	0	7.62M
Total Assets+	113.17K	405K	109.39M	412.49M	515.56M	405.84M	666.71M	776.22M
Asset Turnover	-	-	-	-	-	-	-	-
Asset Growth %	-	2.58%	269.09%	2.77%	0.25%	-0.21%	0.64%	0.16%
Total Current Liabilities+	1.61M	380.45K	15.32M	18.77M	44.52M	43.3M	48.61M	68.78M
Accounts Payable	1.14M	0	1.19M	2.43M	18.63M	1.35M	7.16M	17.66M
Days Payables Outstanding	-	-	20.68K	-	-	-	-	-
Short-Term Debt	0	300K	3.19M	0	0	0	138K	0
Deferred Revenue (Current)	0	-206	0	0	0	0	0	0
Other Current Liabilities	0	-206	10.94M	3.14M	171K	350K	26.57M	15.62M
Current Ratio	0.07x	0.85x	7.12x	21.79x	11.52x	9.34x	13.70x	11.16x
Quick Ratio	0.07x	0.85x	7.12x	21.79x	11.52x	9.34x	13.70x	11.16x
Cash Conversion Cycle	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	0	300K	0	2.24M	1.22M	47K	347K	0
Long-Term Debt	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	2.24M	1.22M	47K	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	347K	0
Other Non-Current Liabilities	0	0	0	0	0	0	0	0
Total Liabilities	1.61M	380.45K	15.32M	21.01M	45.74M	43.34M	48.95M	68.78M
Total Debt+	0	300K	3.19M	3.42M	2.36M	1.22M	138K	98K
Net Debt	0	-25K	-97.38M	-396.73M	-491.45M	-375.31M	-635.23M	-713.87M
Debt / Equity	-	12.22x	0.03x	0.01x	0.01x	0.00x	0.00x	0.00x
Debt / EBITDA	-	31.41x	-	-	-	-	-	-
Net Debt / EBITDA	-	-2.62x	-	-	-	-	-	-
Interest Coverage	-	-	-95.48x	-	-	-16.69x	-	-
Total Equity+	-1.5M	24.55K	94.07M	391.48M	469.82M	362.49M	617.76M	707.45M
Equity Growth %	-	1.02%	3830.42%	3.16%	0.2%	-0.23%	0.7%	0.15%
Book Value per Share	-0.15	0.00	2.18	4.46	4.28	2.95	4.47	4.67
Total Shareholders' Equity	-1.5M	24.55K	94.07M	391.48M	469.82M	362.49M	617.76M	707.45M
Common Stock	0	288	5K	10K	12K	13K	14K	16K
Retained Earnings	0	-448	-91.23M	-198.66M	-355.39M	-566.35M	-825.68M	-1.24B
Treasury Stock	0	0	0	0	0	0	0	0
Accumulated OCI	-1.5M	343K	-16K	-298K	404K	852K	1.91M	1.46M
Minority Interest	0	0	0	0	0	0	0	0

Cash Flow

	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operations+	-128.3M	-28.55M	-53.36M	-83.33M	-106.11M	-188.19M	-214.23M	-375.87M
Operating CF Margin %	-	-	-	-	-	-	-	-
Operating CF Growth %	-	0.78%	-0.87%	-0.56%	-0.27%	-0.77%	-0.14%	-0.75%
Net Income	-136.74M	-28.6M	-66.39M	-107.43M	-156.73M	-210.96M	-259.34M	-413.84M
Depreciation & Amortization	0	10K	21K	998K	126K	193K	231K	377K
Stock-Based Compensation	1.81M	1.31M	6.96M	0	34.24M	32.3M	41.12M	49.49M
Deferred Taxes	0	0	0	0	0	0	0	0
Other Non-Cash Items	5.19M	-792K	1.24M	18.54M	1.11M	1.13M	1.13M	133K
Working Capital Changes	1.44M	-474K	4.81M	4.57M	15.14M	-10.85M	2.63M	-12.03M
Change in Receivables	0	0	-83K	2.5M	-11.72M	12.22M	-4.56M	2.97M
Change in Inventory	0	0	0	0	0	0	0	0
Change in Payables	0	0	967K	1.25M	16.25M	-17.12M	5.78M	10.68M
Cash from Investing+	0	-52K	-31K	-210K	-254K	-197K	-360K	-759K
Capital Expenditures	0	-52K	-31K	-210K	-254K	-197K	-360K	-759K
CapEx % of Revenue	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0	0	0
Cash from Financing+	128.3M	35.58M	146.97M	383.11M	200.13M	70.89M	472.43M	454.49M
Debt Issued (Net)	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-
Other Financing	128.3M	35.58M	109.07M	0	200.13M	385K	-318K	4.49M
Net Change in Cash	-	-	-	-	-	-	-	-
Free Cash Flow+	-128.3M	-28.6M	-53.39M	-83.54M	-106.37M	-188.39M	-214.59M	-376.63M
FCF Margin %	-	-	-	-	-	-	-	-
FCF Growth %	-	0.78%	-0.87%	-0.56%	-0.27%	-0.77%	-0.14%	-0.76%
FCF per Share	-12.83	-1.99	-1.24	-0.95	-0.97	-1.53	-1.55	-2.48
FCF Conversion (FCF/Net Income)	0.94x	63720.98x	0.80x	0.78x	0.68x	0.89x	0.83x	0.91x
Interest Paid	0	0	0	0	0	0	0	0
Taxes Paid	0	0	61K	0	0	0	509K	1.2M

Key Ratios

Metric	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	-	-1.82%	-141.11%	-44.25%	-36.39%	-50.69%	-52.91%	-62.46%
Debt / Equity	-	12.22x	0.03x	0.01x	0.01x	0.00x	0.00x	0.00x
Interest Coverage	-	-	-95.48x	-	-	-16.69x	-	-
FCF Conversion	0.94x	63720.98x	0.80x	0.78x	0.68x	0.89x	0.83x	0.91x

Frequently Asked Questions

Growth & Financials

Immunovant, Inc. (IMVT) grew revenue by 0.0% over the past year. Growth has been modest.

Immunovant, Inc. (IMVT) reported a net loss of $464.7M for fiscal year 2025.

Dividend & Returns

Immunovant, Inc. (IMVT) has a return on equity (ROE) of -62.5%. Negative ROE indicates the company is unprofitable.

Immunovant, Inc. (IMVT) had negative free cash flow of $431.3M in fiscal year 2025, likely due to heavy capital investments.